Funding round
Nimbus Therapeutics Growth
Reported as "Growth Equity"
Nimbus Therapeutics, which works in precision small molecule drug discovery in Boston, raised $60M in a Growth round announced on 14 Oct 2020, led by RA Capital. 2 firms took part, 1 of them already investors. It is Nimbus Therapeutics' fourth venture round on record; the one before was a Series B in Mar 2015.
$60M
Amount raised
Not disclosed
Post-money valuation
2
Investors
1 lead
Valuation
What this round says about the price
Nimbus Therapeutics did not disclose a valuation in this round. It came 67 months after Nimbus Therapeutics' Series B. It is 11% of the $569M Nimbus Therapeutics has raised in the venture rounds on record. Nimbus Therapeutics raised again 9 months later: a Growth round of $105M in Jul 2021.
Nimbus Therapeutics' funding rounds
Nimbus Therapeutics has 7 venture rounds on record. This one is highlighted.
- Seed 1 Mar 2011 $1.5M
- Series A 28 Jun 2011, led by Atlas Venture, SR One and Lilly Ventures $24M
- Series B 18 Mar 2015, led by Pfizer Venture Investments and Lightstone Ventures $43M
- Growth this round 14 Oct 2020, led by RA Capital $60M
- Growth 13 Jul 2021, led by BVF Partners L.P. $105M
- Growth 12 Sep 2022, led by Bain Capital Life Sciences and SV Health Investors $125M
- Growth 6 Sep 2023, led by GV, SR One and Atlas Venture $210M
Investors
Who put money in
RA Capital led the round with 1 other firm. RA Capital had backed Nimbus Therapeutics before.
Lead investor
- backs 109 venture-backed companies existing investor
Also in the round
- BVF Partners L.P. new investor
Joined the board: Laura Stoppel (RA Capital Management).
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
21 Growth rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $55M, and this round was close to the median. The closest in time, other companies' Growth rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Cerevel Pharmaceutical Products | 27 Oct 2020 | $440M | not disclosed | Perceptive Advisors |
| Pharmaceutical Products | 18 Jan 2021 | $14M | not disclosed | ADM Capital Europe and Cibus Fund |
| Pharmaceutical Products | 17 Feb 2021 | $77M | not disclosed | not named |
| Pharmaceutical Products | 19 Feb 2021 | $35M | not disclosed | not named |
| Amoun Pharmaceutical Pharmaceutical Products | 31 Mar 2021 | $740M | not disclosed | not named |
| Cerevel Pharmaceutical Products | 13 Apr 2021 | $125M | not disclosed | not named |
| Pharmaceutical Products | 12 Apr 2021 | $100M | not disclosed | not named |
| RemeGen Pharmaceutical Products | 2 Apr 2020 | $100M | not disclosed | Lilly Asia Ventures and Lake Bleu Capital |
Sources
Where this comes from
Reported by 4 sources.
Questions
Frequently asked
How much did Nimbus Therapeutics raise in its Growth round?
Nimbus Therapeutics raised $60M in its Growth round, announced in Oct 2020.
Who led Nimbus Therapeutics' Growth round?
RA Capital led it, with BVF Partners L.P..
What was Nimbus Therapeutics' valuation at the Growth round?
It was not disclosed.
How does it compare with other Growth rounds in Pharmaceutical Products?
21 Growth rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $55M, and this round was close to the median.
Did Nimbus Therapeutics raise again after this round?
Yes: a Growth round in Jul 2021 of $105M.